Back
Compare AU
Compare BGBL vs. DRUG
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Betashares Global Shares ETF (BGBL) and the Betashares Global Healthcare Currency Hedged ETF (DRUG). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
BGBL | DRUG | |
|---|---|---|
Popularity | Medium | Low |
Pearlers invested | 1,355 | 72 |
Median incremental investment | $2,000.00 | $740.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $6,099.12 | $2,076.48 |
Average age group | 26 - 35 | > 35 |
Key Summary
BGBL | DRUG | |
|---|---|---|
Strategy | BGBL.AX was created on 2023-05-09 by BetaShares. The fund's investment portfolio concentrates primarily on total market equity. The investment objective of the Betashares Global Shares ETF is to provide an investment return that aims to track the performance of the Solactive GBS Developed Markets ex Australia Large & Mid Cap Index (the Index), before taking into account fees and expenses. | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. |
Top 3 holdings | MSCI WORLD INDEX SEP26 (0 %) NVIDIA CORP (5.56 %) APPLE INC (4.96 %) | CHF - SWISS FRANC (0 %) AUD - AUSTRALIA DOLLAR (0 %) BRL - BRAZILIAN REAL (0 %) |
Top 3 industries | Other (29.74 %) Information Technology (25.04 %) Financials (8.88 %) | Other (75.91 %) Communication Services (33.53 %) Health Care (23.80 %) |
Top 3 countries | United States (72.14 %) Japan (6.29 %) United Kingdom of Great Britain and Northern Ireland (3.69 %) | United States (69.91 %) Switzerland (10.93 %) United Kingdom of Great Britain and Northern Ireland (7.38 %) |
Management fee | 0.08 % | 0.57 % |
Key Summary
BGBL | DRUG | |
|---|---|---|
Issuer | BetaShares | BetaShares |
Tracking index | Solactive GBS Developed Markets ex Australia Large & Mid Cap AUD Index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD |
Asset class | ETF | ETF |
Management fee | 0.08 % | 0.57 % |
Price | $85.03 | $9.27 |
Size | $4.963 billion | $175.833 million |
10Y return | N/A | 89.57 % |
Annual distribution yield (5Y) | 1.05 % | 1.82 % |
Market | ASX | ASX |
First listed date | 10/05/2023 | 08/08/2016 |
Purchase fee | $6.50 | $6.50 |
Community Stats
BGBL | DRUG | |
|---|---|---|
Popularity | Medium | Low |
Pearlers invested | 1,355 | 72 |
Median incremental investment | $2,000.00 | $740.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $6,099.12 | $2,076.48 |
Average age group | 26 - 35 | > 35 |
Pros and Cons
BGBL | DRUG | |
|---|---|---|
Pros |
|
|
Cons |
|
|
BGBL | DRUG |
|---|---|
Higher exposure to AU market | Lower exposure to AU market |
Higher exposure to US market | Lower exposure to US market |
Lower management fee | Higher management fee |
Lower price growth | Higher price growth |
Lower distribution yield | Higher distribution yield |